| Clinical Information | Administration Information |
|---|---|
|
Indication: Solid Tumors Condition: Mild hepatic impairment (Child-Pugh A) |
Dose: by mouth – 100 mg Frequency: twice daily Duration: Continue until disease progression or until unacceptable toxicity Note: No dosage adjustment necessary |
|
Indication: Solid Tumors Condition: Moderate to severe hepatic impairment (Child-Pugh B or C) |
Dose: by mouth – Reduce starting dose by 50% Frequency: twice daily Duration: Continue until disease progression or until unacceptable toxicity |
| Clinical Information | Administration Information |
|---|---|
|
Indication: Solid Tumors Condition: Body surface area less than 1 m2 |
Dose: Oral – 100 mg/m2 Frequency: twice daily Note: by mouth (oral), Continue until disease progression or until unacceptable toxicity, Indicated for treatment of patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment |
|
Indication: Solid Tumors Condition: Body surface area greater than 1 m2 |
Dose: Oral – 100 mg Frequency: twice daily Note: by mouth (oral), Continue until disease progression or until unacceptable toxicity, Indicated for treatment of patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment |
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild to severe |
Dose: No dosage adjustment necessary Note: Renal impairment Mild to severe: No dosage adjustment necessary |
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A4 inhibitors
|
May increase larotrectinib plasma concentrations and potentially result in higher incidence of adverse reactions
|
|
Strong CYP3A4 inducers
|
May decrease larotrectinib plasma concentrations, which may decrease efficacy
|
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.